PARP-ARPI Combo Sets New Standard for Metastatic Hormone-Sensitive Prostate Cancer

(MedPage Today) -- CHICAGO -- Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received a PARP inhibitor in addition...